Company intelligence / Profile preview
EmphyCorp Inc.
Flemington, New Jersey, United Statesemphycorp.com ↗
- Ownership
- Private
- Development stage
- Phase 3
01
Overview
Completed three successful Phase III clinical trials for N115 Nasal Spray for Pulmonary Fibrosis, COVID-19, and COVID-19 Long Haulers treatments. The product has demonstrated efficacy with no known side effects in all lung and sinus diseases tested. N115 produced statistically significant increases in lung functions with reduction in inflammation, oxygen radicals, congestion, coughing, fatigue, and inflammatory cytokines including IL-6.
- Therapeutic areas
- PulmonologyOncologyImmunologyNeurologyInfectious Diseases
- Modalities
- Non-steroidal nasal sprayoral spray
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on EmphyCorp Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EmphyCorp Inc..